ERVW-1 and neoplasm: Considering that both antibody as well as T cell responses against MelARV Env are beneficial for the prevention of CT26 tumor growth [11, 25–28] the current Ad5-MelARV vaccine tested in this study could be improved by inducing higher antibody levels.